TAKEDA PHARMACEUTICAL CO LTD
Business
TAKEDA PHARMACEUTICAL CO LTD is a global, values-based, R&D-driven biopharmaceutical company engaged in the research, development, production and global commercialization of pharmaceutical and vaccine products. It offers innovative prescription medicines, plasma-derived therapies, vaccines and related R&D and manufacturing services across modalities including biologics, small molecules, peptides and cell therapies. The company’s operations are organized into six key business areas—Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines and Neuroscience—and dedicated R&D units for Innovative Biopharma, PDT and Vaccines. Takeda markets and distributes its products worldwide with major commercial focus in the United States, Japan, Europe and China, and operates regional business units and a network of manufacturing and plasma donation centers.
Summary from filing dated 2025-06-25
Financials
Latest annual snapshot (FY2025, period end 2025-03-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $108.14B |
| Total assets | $14.25T |
| Total liabilities | $7.31T |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Holdings (13F)
Portfolio as of 2025-09-30 · 9 positions
Top sectors
| Sector | Value | % of portfolio |
|---|---|---|
| Uncategorized | $16.37M | 100.0% |
Top holdings
| Issuer | Ticker | Shares | Value | % |
|---|---|---|---|---|
| Ovid Therapeutics, Inc. | — | 5.75M | $7.47M | 45.7% |
| Equillium, Inc. | — | 1.82M | $2.61M | 15.9% |
| Ovid Therapeutics, Inc. | — | 1.78M | $2.32M | 14.2% |
| Xilio Therapeutics, Inc. (formerly Akrevia Therapeutics) | — | 1.48M | $1.24M | 7.6% |
| Shattuck Labs, Inc. | — | 515.6K | $1.23M | 7.5% |
| Lyell Immunopharma, Inc. | — | 54.9K | $891.0K | 5.4% |
| American Well Corporation | — | 77.7K | $478.0K | 2.9% |
| Rani Therapeutics Holdings, Inc. | — | 203.2K | $101.0K | 0.6% |
| Standard Biotools, Inc. | — | 16.5K | $21.0K | 0.1% |